Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells
Lucie Heinzerling, Valérie Künzi, Patrick A. Oberholzer, et al.
Blood (2005) Vol. 106, Iss. 7, pp. 2287-2294
Open Access | Times Cited: 177

Showing 1-25 of 177 citing articles:

Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi‐Boateng, Jessica L. Pettigrew, Young Kwok, et al.
Nature reviews. Cancer (2018) Vol. 18, Iss. 7, pp. 419-432
Closed Access | Times Cited: 358
Oncolytic viruses in cancer therapy
Markus Vähä‐Koskela, Jari Heikkilä, Ari Hinkkanen
Cancer Letters (2007) Vol. 254, Iss. 2, pp. 178-216
Open Access | Times Cited: 334
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Alan Melcher, Kelley A. Parato, Cliona M. Rooney, et al.
Molecular Therapy (2011) Vol. 19, Iss. 6, pp. 1008-1016
Open Access | Times Cited: 230
Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma
Weiwei Dai, Ruotong Tian, Liubing Yu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 18
Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers
P. Seshidhar Reddy, Kevin D. Burroughs, Laura M. Hales, et al.
JNCI Journal of the National Cancer Institute (2007) Vol. 99, Iss. 21, pp. 1623-1633
Open Access | Times Cited: 223
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Youn H. Kim, Dita Gratzinger, Cameron Harrison, et al.
Blood (2011) Vol. 119, Iss. 2, pp. 355-363
Open Access | Times Cited: 206
Intelligent Design: Combination Therapy With Oncolytic Viruses
Kathryn Ottolino‐Perry, Jean‐Simon Diallo, Brian D. Lichty, et al.
Molecular Therapy (2009) Vol. 18, Iss. 2, pp. 251-263
Open Access | Times Cited: 197
Measles virus causes immunogenic cell death in human melanoma
Oliver Donnelly, Fiona Errington‐Mais, Lynette P. Steele, et al.
Gene Therapy (2011) Vol. 20, Iss. 1, pp. 7-15
Open Access | Times Cited: 174
Measles Virus for Cancer Therapy
Stephen J. Russell, Kah-Whye Peng
Current topics in microbiology and immunology (2008), pp. 213-241
Open Access | Times Cited: 170
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Sònia Guedan, Ramón Alemany
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 126
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Pavlos Msaouel, Mateusz Opyrchal, Angela Dispenzieri, et al.
Current Cancer Drug Targets (2017) Vol. 18, Iss. 2, pp. 177-187
Open Access | Times Cited: 122
Specific Elimination of CD133+ Tumor Cells with Targeted Oncolytic Measles Virus
Patricia Bach, Tobias Abel, Christopher M. Hoffmann, et al.
Cancer Research (2013) Vol. 73, Iss. 2, pp. 865-874
Open Access | Times Cited: 120
The emerging role of oncolytic virus therapy against cancer
Luke Russell, Kah-Whye Peng
Chinese Clinical Oncology (2018) Vol. 7, Iss. 2, pp. 16-16
Open Access | Times Cited: 117
Measles to the Rescue: A Review of Oncolytic Measles Virus
Sarah Aref, Katharine Bailey, Adele K. Fielding
Viruses (2016) Vol. 8, Iss. 10, pp. 294-294
Open Access | Times Cited: 115
Measles Virus Vaccine–Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells
Jean-Baptiste Guillerme, Nicolas Boisgerault, David Roulois, et al.
Clinical Cancer Research (2013) Vol. 19, Iss. 5, pp. 1147-1158
Open Access | Times Cited: 112
Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
Tobias Speck, Johannes P.W. Heidbuechel, Rūta Veinalde, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 9, pp. 2128-2137
Open Access | Times Cited: 94
The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein
Liang Lin, C. Richardson
Viruses (2016) Vol. 8, Iss. 9, pp. 250-250
Open Access | Times Cited: 91
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
Egle Ramelyte, Aizhan Tastanova, Zsolt Balázs, et al.
Cancer Cell (2021) Vol. 39, Iss. 3, pp. 394-406.e4
Open Access | Times Cited: 91
Talimogene Laherparepvec: Review of its Mechanism of Action and Clinical Efficacy and Safety
Steven S. Raman, J. Randolph Hecht, Emily Chan
Immunotherapy (2019) Vol. 11, Iss. 8, pp. 705-723
Open Access | Times Cited: 88
Clinical Application of Oncolytic Viruses: A Systematic Review
Mary A. Cook, Aman Chauhan
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 20, pp. 7505-7505
Open Access | Times Cited: 79
Self-Amplifying RNA Viruses as RNA Vaccines
Kenneth Lundström
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5130-5130
Open Access | Times Cited: 77
Oncolytic virotherapy: Challenges and solutions
Nasser Hashemi Goradel, Alexander T. Baker, Arash Arashkia, et al.
Current Problems in Cancer (2020) Vol. 45, Iss. 1, pp. 100639-100639
Closed Access | Times Cited: 77
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
Norihiro Watanabe, Mary K. McKenna, Amanda Rosewell Shaw, et al.
Molecular Therapy (2020) Vol. 29, Iss. 2, pp. 505-520
Open Access | Times Cited: 70
Measles Virus as an Oncolytic Immunotherapy
Christine E. Engeland, Guy Ungerechts
Cancers (2021) Vol. 13, Iss. 3, pp. 544-544
Open Access | Times Cited: 70
Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy
Ramazan Rezaei, Hadi Esmaeili Gouvarchin Ghaleh, Mahdieh Farzanehpour, et al.
Cancer Gene Therapy (2021) Vol. 29, Iss. 6, pp. 647-660
Open Access | Times Cited: 66
Page 1 - Next Page

Scroll to top